Compound Contains Two Or More C(=o)o Groups Patents (Class 514/547)
-
Publication number: 20120258159Abstract: A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water.Type: ApplicationFiled: April 3, 2012Publication date: October 11, 2012Applicant: HERAEUS MEDICAL GMBHInventor: Sebastian VOGT
-
Publication number: 20120259010Abstract: A cosmetic composition is provided which includes a diester quit and a small amount of a potassium salt in an aqueous carrier. Preferably the compositions are lotions and creams which have the benefit of smooth spreadability in topical application onto the skin.Type: ApplicationFiled: April 11, 2011Publication date: October 11, 2012Applicant: CONOPCO, INC., D/B/A UNILEVERInventor: LUIS ROBERTO MISSO
-
Publication number: 20120259011Abstract: A personal care composition is provided which includes a diester quat and a polyhydroxy quaternary ammonium salt. Preferably the composition is a lotion or cream which exhibits a dragginess in topical application onto the skin.Type: ApplicationFiled: April 11, 2011Publication date: October 11, 2012Applicant: CONOPCO, INC., D/B/A UNILEVERInventor: LUIS ROBERTO MISSO
-
Publication number: 20120251525Abstract: The treatment of disease in organisms using Macromolecular interaction modulators and Membrane active immunomodulators, particularly selected azelaic acid esters, individually and in combinations, to modulate communications between biological molecules.Type: ApplicationFiled: April 18, 2012Publication date: October 4, 2012Inventors: Robert T. Streeper, Elzbieta Izbicka
-
Patent number: 8273796Abstract: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with a combination of a monohydroxy functional amine and a specific di-hydroxy functional tertiary alkanolamine, to make an ester tertiary amine, which is a subsequent step is converted to a quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and reacting it with the two type of amine groups allow for the synthesis of a high molecular weight cationic compound which is extremely substantitive to human skin and are well tolerated by human tissue making them suitable for use preparation of barrier products for personal care applications. These materials are dimethylaminopropyl amine free, which is highly desirable in personal care applications.Type: GrantFiled: June 1, 2010Date of Patent: September 25, 2012Assignee: SurfaTech CorporationInventors: Kevin A. O'Lenick, Anthony J. O'Lenick, Jr.
-
Publication number: 20120238521Abstract: The invention is directed to a composition and associated method for the treatment of musculoskeletal related disorders and diseases. In particular, the present invention provides a class of citrate compounds that can be used to for the treatment of diseases/disorders characterized by the degeneration of musculoskeletal tissues including menisci, bone, articular cartilage, and soft tissues. Examples of suitable citrate and citrate analog compounds include citrates having the following base formula (I): where X may be one of the following: wherein Y, Y?, and Y? are independently a citrate moiety, O, O—Y, OH, NH, NH—Y, R and R—Y, with R being an alkyl, alkyene, ester, aryl, or phenyl group having from 1 to 6 carbon atoms.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: The Charlotte-Mecklenbury Hospital Authority d/b/a Carolinas Medical CenterInventors: Yubo Sun, Edward N. Hanley
-
Patent number: 8268884Abstract: The present invention relates to compounds represented by formula (I), or isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof: in which each substituent of formula (I) is as defined in the specification. The present invention also relates to preparation methods of compounds represented by formula (I), a pharmaceutical composition comprising compounds represented by formula (I) and usage of compounds represented by formula (I) for treating chronic neurodegenerative diseases such as Alzheimer's disease and other diseases induced by aggregation or deposition of ?-amyloid peptide.Type: GrantFiled: February 5, 2007Date of Patent: September 18, 2012Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Guochao Liao, Junhai Xiao, Aihua Nie, Lili Wang, Wu Zhong, Zhibing Zheng
-
COMPOSITIONS COMPRISING A FATTY ACID OIL MIXTURE AND A FREE FATTY ACID, AND METHODS AND USES THEREOF
Publication number: 20120232141Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.Type: ApplicationFiled: March 9, 2010Publication date: September 13, 2012Inventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Müllertz -
Publication number: 20120232142Abstract: Disclosed are a pharmaceutical composition for inhibiting vascular smooth muscle cell proliferation comprising dimethyl fumarate as an effective ingredient, use of dimethyl fumarate for inhibiting vascular smooth muscle cell proliferation, and a method of inhibiting vascular smooth muscle cell proliferation employing the same. Through the present invention, it was found that dimethyl fumarate could inhibit vascular smooth muscle cell proliferation by increasing the activity of AMPK. Accordingly, dimethyl fumarate can be usefully used as an effective ingredient of a medicine for inhibiting vascular smooth muscle cell proliferation.Type: ApplicationFiled: March 1, 2012Publication date: September 13, 2012Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventor: In Kyu LEE
-
Patent number: 8257478Abstract: Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2,5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings.Type: GrantFiled: December 16, 2005Date of Patent: September 4, 2012Assignee: The Hong Kong University of Science and TechnologyInventors: Pei-Yuan Qian, Xiancui Li, Fuk Ning Kwong, Lai Hung Yang, Sergey Vladimirovich Dobretsov
-
Publication number: 20120219647Abstract: The present invention relates to compositions comprising an edible oil having improved oxidative stability and methods for manufacturing such compositions. The composition contains an active fraction of a green tea extract, partial glycerides in an amount of at least 2% and an edible oil. The partial glycerides may contain mono- and/or diglycerides and the edible oil may be a polyunsaturated oil, e.g. a fish oil.Type: ApplicationFiled: July 20, 2010Publication date: August 30, 2012Inventors: Harald Breivik, Vidar Moen, Tanja Vojnovic
-
Publication number: 20120220596Abstract: The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicants: UWM RESEARCH FOUNDATION, INC., MARQUETTE UNIVERSITYInventors: James M. Cook, David A. Baker, Wenyuan Yin, Edward Merle Johnson, II
-
Publication number: 20120208883Abstract: The present invention relates to the use of acetyl L-carnitine for the preparation of a medicament for the prevention and/or treatment of cancer. Methods of preventing and/or treatment of cancer by administering an effective amount of acetyl L-carnitine to subject in need thereof are also disclosed.Type: ApplicationFiled: December 1, 2009Publication date: August 16, 2012Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.AInventors: Claudio Cavazza, Anna Atti, Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza, Paolo Carminati, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati, Claudio Pisano
-
Publication number: 20120207730Abstract: Disclosed herein are methods and compositions for treating viral hemorrhagic fever in a subject by use of at least one inhibitor or suppressor of oxidase, inducible nitric oxide synthase (iNOS) and apoptosis pathway.Type: ApplicationFiled: April 30, 2012Publication date: August 16, 2012Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Betty A. Wu-Hsieh, Yu-Ting Yen
-
Patent number: 8242172Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: GrantFiled: July 14, 2010Date of Patent: August 14, 2012Assignee: Trustees of Boston UniversityInventor: Susan P. Perrine
-
Patent number: 8236854Abstract: A lipid-improving agent containing a triglyceride(s) where a poly-unsaturated fatty acid is bonded to 2-position of a triglyceride(s).Type: GrantFiled: April 5, 2010Date of Patent: August 7, 2012Assignee: Suntory Holdings LimitedInventors: Kengo Akimoto, Harukazu Fukami, Toshinao Goda
-
Publication number: 20120198590Abstract: The disclosure pertains to isolated white pine toxigenic endophytes and the compounds produced by the fungal endophytes as well as methods and uses of the white pine endophytes. The isolated white pine toxigenic endophytes are useful for preparing white pine seedlings and plants that have increased tolerance to a pest and are prepared by inoculating a white pine seedling during the susceptible time window.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Applicant: J.D. IRVING, LIMITEDInventors: John David Miller, Greg William Adams, Mark Sumarah
-
Publication number: 20120196835Abstract: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to inhibit bacterial or parasite growth. The invention further provides inhibitors of isoprenoid biosynthesis enzymes, and methods of inhibiting the activity of isoprenoid biosynthesis enzymes. The compounds can be, for example, alkynes or allenes that bind to a unique Fe of an Fe4S4 cluster of an isoprenoid biosynthesis enzyme.Type: ApplicationFiled: October 8, 2010Publication date: August 2, 2012Inventors: Eric Olafield, Ke Wang, Weixue Wang, Yonghui Zhang
-
Publication number: 20120195850Abstract: The invention provides method for sequestering or trapping L-lactate in or near a tumor cell comprising contacting an isolated polymer of D-lactic acid (PDLA) or an equivalent, derivative or analog thereof with the tumor cell so that the PDLA binds L-lactate in or near the cell and thereby sequestering or trapping L-lactate in or near the tumor cells.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Inventors: Joel S. Goldberg, Joe Brice Weinberg
-
Publication number: 20120196932Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.Type: ApplicationFiled: April 12, 2012Publication date: August 2, 2012Applicant: ACCERA, INC.Inventor: Samuel T. Henderson
-
Publication number: 20120195963Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.Type: ApplicationFiled: April 4, 2012Publication date: August 2, 2012Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Malcolm Peet, Krishna S. Vaddadi
-
Publication number: 20120196931Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.Type: ApplicationFiled: February 13, 2012Publication date: August 2, 2012Applicant: Biogen Idec MA Inc.Inventors: Matvey E. LUKASHEV, Gilmore O'Neill
-
Publication number: 20120189709Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Debra L. Thomas, Pradip Mukerji
-
Patent number: 8227460Abstract: Composition comprising a polymerizable compound with at least one conjugated unsaturated group and methylene blue to prevent premature polymerization of the polymerizable compound. The methylene blue is present in a concentration of 10 to 5000 ppm.Type: GrantFiled: May 4, 2010Date of Patent: July 24, 2012Assignee: Straumann Holding AGInventor: Aaldert Molenberg
-
Publication number: 20120177744Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ABBOTT LABORATORIESInventors: Debra L. Thomas, Pradip Mukerji
-
Publication number: 20120178721Abstract: Method of using immunomodulatory compounds for treating diseases related to an overproduction of inflammatory cytokines, including diseases selected from asthma, atopic dermatitis, allergic rhinitis, prostatitis, inflammatory bowel disease, diabetes, and rheumatoid arthritis, the compounds being of general formula (I): wherein : m and n, independently from each other, are an integer ranging from 1 to 4, X and Y represent —COOH, —O—P(O)(OH)2, —O—SO2(OH), —NH2, —OH, —CONH(CH2)n1—NH2, —CO—NH—CH(COOH)—(CH2)n1—COOH, —CO—NH—CH(COOH)—(CH2)n1—NH2)—O—CO—(CH2)n1—NH2, —O—CO—(CH2)n1—CHOH—CH2OH, —O—CO—(CH2)n1—OH, —O—CO—(CH2)n1—COOH, —O—Co—(CH2)n1—CHO, —O—CO—(CH2)n1—NH—CO—(CH2)n2—COOH, —R1 and R2 each designate an acyl group derived from a saturated or unsaturated, straight-or branched-chain carboxylic acid having from 2 to 18 carbon atoms, which is unsubstituted or bears one to three substituents selected among hydroxyl, dihydroxyphosphoryloxy, alkyl of 2 to 18 carbon atoms, alkoxy of 2 to 18 carbon atoms, acylType: ApplicationFiled: March 28, 2011Publication date: July 12, 2012Applicant: OM PHARMAInventors: Jacques BAUER, Carlo CHIAVAROLI, Stephane MOUTEL
-
Publication number: 20120172326Abstract: The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or Ichthyosis vulgaris containing a synergistic combination among its constituents, and cosmetic and/ pharmaceutical compositions containing said moisturizing mixture. The invention also refers to a moisturizing mixture comprising a synergistic combination between at least one cutaneous-barrier repairing agent; NMF-precursor amino acids; and at least one filagrin-synthesis stimulating agent. Cosmetic and/or pharmaceutical compositions comprising said moisturizing mixture and a physiologically acceptable carrier are also described in the present invention.Type: ApplicationFiled: November 27, 2009Publication date: July 5, 2012Applicant: Natura Cosmeticos S.A.Inventors: Patricia Da Luz Moreira, Adriano Tadeu Siqueira Jorge, Juliana Palmeira Portugal Marques, Jean Luc Gesztesi, Philip Leite Ribeiro, Sara Rocha
-
Patent number: 8211942Abstract: Compositions and methods to inhibit dry eye as well as other conditions are provided.Type: GrantFiled: January 26, 2011Date of Patent: July 3, 2012Inventor: Irvine L. Dubow
-
Publication number: 20120165404Abstract: Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroinflammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.Type: ApplicationFiled: April 29, 2010Publication date: June 28, 2012Applicant: Biogen Idec MA Inc.Inventor: Matvey Lukashev
-
Publication number: 20120165405Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.Type: ApplicationFiled: December 30, 2011Publication date: June 28, 2012Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Alexandra Dürr, Fanny Mochel
-
Patent number: 8206751Abstract: The subject invention relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders.Type: GrantFiled: October 31, 2008Date of Patent: June 26, 2012Assignee: Diffusion Pharmaceuticals LLCInventor: John L. Gainer
-
Publication number: 20120157523Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: ApplicationFiled: October 14, 2011Publication date: June 21, 2012Applicant: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Publication number: 20120142773Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.Type: ApplicationFiled: April 29, 2010Publication date: June 7, 2012Applicant: DIGNITY SCIENCES LIMITEDInventors: Adam Kelliher, Angus Morrison, Phil Knowles
-
Publication number: 20120142590Abstract: The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.Type: ApplicationFiled: October 14, 2011Publication date: June 7, 2012Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Adam N. Goldfarb, Loretta L. Delehanty
-
Publication number: 20120129933Abstract: The invention relates to ceramide dimers which are constructed from two ceramide molecules which are crosslinked to each other via their lipophilic end. The ceramide molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the dimer. The ceramide dimers according to the invention can be used as pharmaceutical preparation or as cosmetic preparation.Type: ApplicationFiled: June 23, 2010Publication date: May 24, 2012Inventor: Hans-Uwe Wolf
-
Publication number: 20120128770Abstract: The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes mellitus (T2DM), obesity, insulin resistance, and cardiovascular disease.Type: ApplicationFiled: June 24, 2010Publication date: May 24, 2012Applicant: Kobenhavns UniversitetInventors: Harald S. Hansen, Thi Ai Diep, Jens Juul Holst, Mette Marie Rosenkilde, Niels Wellner Andersen
-
Publication number: 20120122978Abstract: This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: ACCERA, INC.Inventor: Samuel T. Henderson
-
Publication number: 20120121720Abstract: This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of ?2 adrenergic receptors or need for increased 132 adrenergic receptor activity.Type: ApplicationFiled: March 31, 2010Publication date: May 17, 2012Inventors: Jonathan S. Stamler, Liang Xie
-
Patent number: 8178713Abstract: The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.Type: GrantFiled: June 16, 2003Date of Patent: May 15, 2012Assignee: Pronovo Biopharma Norge ASInventors: Andrew David Miller, Michael R. Jørgensen, Rolf Kristian Berge, Jon Skorve
-
Patent number: 8173618Abstract: Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).Type: GrantFiled: July 23, 2004Date of Patent: May 8, 2012Assignee: University of MassachusettsInventors: Thomas B. Shea, Robert J. Nicolosi, Eugene Rogers
-
Publication number: 20120101060Abstract: The invention relates to a skin protectant, particularly against hydrophobic (lipophilic) and hydrophilic (lipophobic) harmful substances, obtainable by means of an amount of at least one barrier-forming component, particularly against hydrophobic (lipophilic) harmful substances, wherein the nephelometric turbidity unit of the barrier-forming component is determined by means of turbidimetry and at least one barrier-forming component, a 1% solution in water thereof having a nephelometric turbidity unit of greater than 40 (NTU), is used to produce the protectant and a method for producing skin protectants, particularly against hydrophobic (lipophilic) and hydrophilic (lipophobic) harmful substances, where in the barrier-forming component is selected for production of the protectant such that the nephelometric turbidity unit of the barrier-forming component of the skin protectant is determined by means of turbidimetry and at least one barrier-forming component, a 1% solution in water thereof having a nephelometrType: ApplicationFiled: June 30, 2010Publication date: April 26, 2012Applicant: Evonik Stockhausen GmbHInventors: Brigitte Thoerner, Petra Allef, Christian Schmidt, Marcel Veeger, Stefani Schmidt, Tanja Kloeren, Anne Claassen
-
Publication number: 20120100077Abstract: Disclosed is a mixture of amphipathic molecules and a method for modifying cells in vivo by way of membrane fusion with these molecules.Type: ApplicationFiled: July 8, 2010Publication date: April 26, 2012Applicant: FORSCHUNGSZENTRUM JUELICH GMBHInventors: Bernd Hoffmann, Agnes Csiszar, Nils Hersch, Rudolf Merkel
-
Publication number: 20120095003Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: ApplicationFiled: October 14, 2011Publication date: April 19, 2012Applicant: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Publication number: 20120095095Abstract: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.Type: ApplicationFiled: December 23, 2011Publication date: April 19, 2012Applicant: The Trustees of Columbia University in the City of New YorkInventors: Richard J. DECKELBAUM, Susan J. VANNUCCI
-
Patent number: 8158679Abstract: Use of L-carnitine or a pharmaceutically acceptable salt thereof, for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal oedema.Type: GrantFiled: November 21, 2007Date of Patent: April 17, 2012Assignee: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.Inventors: Aleardo Koverech, Nicola Pescosolido
-
Patent number: 8148414Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: GrantFiled: August 19, 2009Date of Patent: April 3, 2012Assignee: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Publication number: 20120076848Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: July 21, 2010Publication date: March 29, 2012Inventor: Kambiz Thomas Moazed
-
Patent number: 8124589Abstract: This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.Type: GrantFiled: April 3, 2007Date of Patent: February 28, 2012Assignee: Accera, Inc.Inventor: Samuel T. Henderson
-
Patent number: 8119688Abstract: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.Type: GrantFiled: September 19, 2007Date of Patent: February 21, 2012Assignee: XY, LLCInventors: Edwin Dean Neas, Thomas Boyd Gilligan
-
Patent number: 8119689Abstract: Bisacyloxycysteine type conjugates have been found to be useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, and allergies, as well as in the control of fertility in human or animal populations. The compounds can be administered by system or mucosal routes and are particularly useful as mucosal adjuvants. These compounds can function as active ingredients in pharmaceutical compositions.Type: GrantFiled: November 22, 2006Date of Patent: February 21, 2012Assignee: Helmholtz-Zentrum Fuer Infektionsforschung GmbHInventors: Thomas Ebensen, Michael Morr, Carlos Guzman